Technical Analysis for RGLS - Regulus Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 1.37 3.01% 0.04
RGLS closed up 3.01 percent on Friday, May 24, 2019, on 70 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical RGLS trend table...

Date Alert Name Type % Chg
Boomer Buy Setup Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 3.01%
Wide Bands Range Expansion -2.84%
Up 3 Days in a Row Strength -2.84%
Upper Bollinger Band Touch Strength -2.84%
MACD Bullish Signal Line Cross Bullish 4.58%
Inside Day Range Contraction 4.58%

Older signals for RGLS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Biopharmaceutical Diseases Genetics Glioblastoma Regulus Therapeutics Hepatocellular Carcinoma RNA Alnylam Pharmaceuticals Hepatitis C Virus Infection Atherosclerosis Microrna Nucleic Acids
Is RGLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.48
52 Week Low 0.8
Average Volume 179,543
200-Day Moving Average 1.5873
50-Day Moving Average 1.1527
20-Day Moving Average 1.252
10-Day Moving Average 1.323
Average True Range 0.1271
ADX 31.49
+DI 32.0675
-DI 13.8284
Chandelier Exit (Long, 3 ATRs ) 1.2382
Chandelier Exit (Short, 3 ATRs ) 1.4413
Upper Bollinger Band 1.4743
Lower Bollinger Band 1.0297
Percent B (%b) 0.77
BandWidth 35.511182
MACD Line 0.057
MACD Signal Line 0.0504
MACD Histogram 0.0067
Fundamentals Value
Market Cap 142.18 Million
Num Shares 104 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -0.90
Price-to-Sales 450.54
Price-to-Book 2.98
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.49
Resistance 3 (R3) 1.49 1.44 1.47
Resistance 2 (R2) 1.44 1.41 1.45 1.46
Resistance 1 (R1) 1.41 1.39 1.43 1.41 1.46
Pivot Point 1.36 1.36 1.37 1.37 1.36
Support 1 (S1) 1.33 1.33 1.35 1.33 1.28
Support 2 (S2) 1.28 1.31 1.29 1.28
Support 3 (S3) 1.25 1.28 1.27
Support 4 (S4) 1.25